TY - JOUR
T1 - Significance of trough monitoring for tacrolimus blood concentration and calcineurin activity in adult patients undergoing primary living-donor liver transplantation
AU - Yano, Ikuko
AU - Masuda, Satohiro
AU - Egawa, Hiroto
AU - Sugimoto, Mitsuhiro
AU - Fukudo, Masahide
AU - Yoshida, Yuko
AU - Hashi, Sachiyo
AU - Yoshizawa, Atsushi
AU - Ogura, Yasuhiro
AU - Ogawa, Kohei
AU - Mori, Akira
AU - Kaido, Toshimi
AU - Uemoto, Shinji
AU - Inui, Ken Ichi
N1 - Funding Information:
Acknowledgments The authors would like to thank Junichi Nomura, Takashi Ikoma, and Ikuo Sekiguchi for their kind assistance. This work was supported in part by a Grant-in-Aid for Scientific Research from the Ministry of Education, Culture, Sports, Science and Technology of Japan.
PY - 2012/3
Y1 - 2012/3
N2 - Purpose: Tacrolimus pharmacokinetics and calcineurin activity in peripheral blood mononuclear cells (PBMCs) were investigated in adult patients undergoing primary living-donor liver transplantation (LDLT) in order to clarify the significance of monitoring the tacrolimus blood trough concentration during the early post-transplantation period. Methods: Fourteen patients were enrolled in this study, and time-course data following the oral administration of a conventional tacrolimus formulation twice daily were obtained at 1 and 3 weeks post-transplantation. The concentration of tacrolimus in whole blood and calcineurin activity in PBMCs were measured. Results: The apparent clearance of tacrolimus significantly increased at 3 weeks versus 1 week post- transplantation, although the trough concentration did not significantly differ at these time points. The concentration at each sampling time, except at 1 h post-dose, correlated well with the area under the concentration-time curve from 0 to 12 h (AUC 0-12). Neither the concentration at the trough time point nor AUC 0-12 was correlated with the area under the calcineurin activity-time curve from 0 to 12 h; however, calcineurin activity at the trough time point was strongly correlated with the latter (r 2 > 0.92). Conclusions: Based on these results, trough concentration monitoring can be considered an appropriate procedure for routine tacrolimus dosage adjustment in adult LDLT patients. Monitoring of calcineurin activity at the trough time point was also found to be potentially useful for predicting the immunological status of the patient during the tacrolimus dosing interval.
AB - Purpose: Tacrolimus pharmacokinetics and calcineurin activity in peripheral blood mononuclear cells (PBMCs) were investigated in adult patients undergoing primary living-donor liver transplantation (LDLT) in order to clarify the significance of monitoring the tacrolimus blood trough concentration during the early post-transplantation period. Methods: Fourteen patients were enrolled in this study, and time-course data following the oral administration of a conventional tacrolimus formulation twice daily were obtained at 1 and 3 weeks post-transplantation. The concentration of tacrolimus in whole blood and calcineurin activity in PBMCs were measured. Results: The apparent clearance of tacrolimus significantly increased at 3 weeks versus 1 week post- transplantation, although the trough concentration did not significantly differ at these time points. The concentration at each sampling time, except at 1 h post-dose, correlated well with the area under the concentration-time curve from 0 to 12 h (AUC 0-12). Neither the concentration at the trough time point nor AUC 0-12 was correlated with the area under the calcineurin activity-time curve from 0 to 12 h; however, calcineurin activity at the trough time point was strongly correlated with the latter (r 2 > 0.92). Conclusions: Based on these results, trough concentration monitoring can be considered an appropriate procedure for routine tacrolimus dosage adjustment in adult LDLT patients. Monitoring of calcineurin activity at the trough time point was also found to be potentially useful for predicting the immunological status of the patient during the tacrolimus dosing interval.
UR - http://www.scopus.com/inward/record.url?scp=84857063368&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84857063368&partnerID=8YFLogxK
U2 - 10.1007/s00228-011-1129-x
DO - 10.1007/s00228-011-1129-x
M3 - Article
C2 - 21969228
AN - SCOPUS:84857063368
SN - 0031-6970
VL - 68
SP - 259
EP - 266
JO - European Journal of Clinical Pharmacology
JF - European Journal of Clinical Pharmacology
IS - 3
ER -